Review proposes precision nanodelivery for NAD⁺ in ageing and disease
This review argues that systemic NAD⁺ precursor supplementation gives uneven tissue distribution and insufficient subcellular restoration, and proposes a hierarchical precision nanodelivery framework for tissue-, cell- and organelle-specific, stimulus-triggered NAD⁺ modulation. [1]
Automatic summary · not editorially reviewed
The key findings
The review states that declining NAD⁺ is a conserved metabolic hallmark of ageing, organ dysfunction and many acute and chronic disorders. [1]
According to the authors, systemic NAD⁺ precursor supplementation gives inconsistent outcomes because of uneven tissue distribution and insufficient subcellular metabolite restoration. [1]
The authors propose a hierarchical precision nanodelivery framework for spatiotemporally programmable NAD⁺ regulation and list translational bottlenecks including compartment-specific biomarkers and stratified safety evaluation. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Pathological tissues and disorders discussed in a review of NAD⁺ metabolism and nanodelivery; no specific study population reported.
- Summary based on
- Study abstract
- Original publication
- September 3, 2026
Why compartmentalized NAD⁺ limits systemic precursors
The review states that declining NAD⁺ is a conserved metabolic hallmark of ageing, organ dysfunction and many acute and chronic disorders. NAD⁺ metabolism is described as strongly compartmentalized by space, cell type and subcellular location in pathological tissue, and as involved in DNA repair, redox balance, inflammatory cascades and mitochondrial energy metabolism. According to the authors, this heterogeneity explains inconsistent therapeutic outcomes of systemic NAD⁺ precursor supplementation, which they say suffers from uneven tissue distribution and insufficient subcellular metabolite restoration.
Supporting source [1]
Proposed nanodelivery framework targets tissue, cell and organelle
The authors advocate a hierarchical precision nanodelivery framework intended to move NAD⁺ therapeutics beyond passive systemic supplementation toward spatiotemporally programmable metabolic regulation. They describe nanodelivery platforms that combine tissue penetration, cellular uptake, organelle targeting and stimulus-triggered cargo release to overcome biological barriers and to match NAD⁺ modulation to defined pathological disease windows. The review summarizes nanodelivery strategies for tissue-, cell- and organelle-specific delivery of NAD⁺, its precursors and metabolic modulators across degenerative, inflammatory and metabolic illnesses.
Supporting source [1]
Translational bottlenecks named; abstract-only review scope
The review lists key translational bottlenecks: compartment-specific biomarkers, stratified safety evaluation, rational dosage regimen, scalable production and individualized patient stratification. The authors argue that the next generation of NAD⁺ therapeutics will be defined not by enhanced bulk supplementation alone but by the capacity to orchestrate precise NAD⁺ manipulation across biological space and time. This is a proposed framework, not a validated or approved product. Only the abstract was reviewed; the full text was not reviewed, so the individual nanodelivery strategies and any supporting data are not assessed here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a proposed framework, not a validated or approved product, and the abstract reports no primary study data, sample or follow-up.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Pei Z, Wang X, Liang F, Zhong M, Jiang Q, Li H. · europepmc.org · September 3, 2026